Homology Medicines, a preclinical biotech developing a gene therapy delivery platform for rare diseases, raised $144 million by offering 9 million shares at $16, the high end of the range of $14 to $16. It previously filed to offer 6.7 million shares at the same range. Homology Medicines plans to list on the Nasdaq under the symbol FIXX. BofA Merrill Lynch, Cowen & Company and Evercore ISI acted as lead managers on the deal.
